Genmab stock climbs on a new $40 call and a 14.57% target gap
Published on 08/18/2026 at 10:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab A/S stock climbed after BNP Paribas started coverage with an Outperform rating and a $40 price target on August 12, 2026. The same consensus page shows 18 analysts, a 2,410.59 DKK average target, and a 14.57% spread to the last close of 2,104.00 DKK.
Analysts are leaning higher
The target band is wide, with a 2,932.00 DKK high and a 1,400.00 DKK low, which leaves a 39.35% upside gap to the top end and a 33.46% downside gap to the low end. That spread says the debate is still centered on execution rather than the stock's basic visibility.
MarketScreener also lists a 5-day move of 2.16% and a 1st Jan change of 1.46%, which gives the rating call a share-price backdrop rather than an isolated note. For investors, the important part is that the new coverage lands after a stronger Q2 read-through already mentioned in the broker flow on the same page.
What the latest view says
The analyst list on the consensus page includes BNP Paribas, Goldman Sachs, UBS, TD Cowen, Nordea Bank, and several other firms, with recent entries showing multiple target hikes in August 2026. That makes the current setup more of a consensus reset than a one-off reaction.
The newest visible research line on the page is August 12, 2026, and it sits alongside several August 7, 2026 updates, including higher targets from UBS, Goldman Sachs, TD Cowen, Jyske Bank, and Nordea. The pattern matters because the market is still digesting a cluster of fresh revisions, not a single isolated change.
Genmab's product base
Genmab's antibody platform remains anchored by its approved oncology medicines and partnered programs, which support the company's earnings story through royalties, milestones, and direct product sales. That mix helps explain why analysts keep framing the stock around pipeline delivery and commercial durability rather than one quarter alone.
Shares and valuation
Genmab stock last closed at 2,104.00 DKK on August 17, 2026, while the average target on the consensus page stands at 2,410.59 DKK. The current discount to that average is 14.57%, and the high target of 2,932.00 DKK leaves room for a 39.35% gap from the last close.
More on Genmab stock
Company: Genmab A/S
ISIN: DK0010272202
Ticker: GMAB
Exchange: Nasdaq Copenhagen
Sector / Industry: Biotechnology / Medical Research
Index membership: OMX Copenhagen 25
View of the day: the stock is trading against a fresh analyst upgrade wave and a target range that still leaves room for more debate than certainty.
